{"id":70765,"date":"2026-05-12T10:53:49","date_gmt":"2026-05-12T10:53:49","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70765"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"cagrisema","status":"publish","type":"product","link":"https:\/\/medsbase.com\/pt-pt\/product\/cagrisema\/","title":{"rendered":"Mistura CagriSema (Cagrilintide 5 mg + Semaglutide 5 mg)"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Resposta R\u00e1pida \u2014 O que \u00e9 CagriSema?<\/h3>\n<p style=\"margin: 0;\"><strong>CagriSema<\/strong> \u00e9 a combina\u00e7\u00e3o coformulada de <a href=\"https:\/\/medsbase.com\/pt-pt\/cagrilintide\/\">cagrilintida<\/a> (an\u00e1logo de amilina de a\u00e7\u00e3o prolongada) e <a href=\"https:\/\/medsbase.com\/pt-pt\/semaglutide\/\">semaglutide<\/a> (agonista de GLP-1 de a\u00e7\u00e3o prolongada) num \u00fanico frasco liofilizado. \u00c9 o principal programa da Novo Nordisk para obesidade na Fase 3 e produziu redu\u00e7\u00f5es de peso corporal de aproximadamente 20\u201323% ao longo de 68 semanas no ensaio REDEFINE-1 \u2014 efeitos compar\u00e1veis aos de triplo-agonista <a href=\"https:\/\/medsbase.com\/pt-pt\/retatrutide\/\">retatrutide<\/a> achieved through the combination of two single-receptor agonists rather than a single multi-agonist molecule. Each vial contains 5\u00a0mg cagrilintide + 5\u00a0mg semaglutide for clinical studies use only.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>O que obt\u00e9m com a MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/pt-pt\/reviews\/\">de clientes<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Cada encomenda est\u00e1 coberta pela nossa <a href=\"https:\/\/medsbase.com\/pt-pt\/medsbase-re-shipment-assurance-policy\/\"><strong>Pol\u00edtica de Garantia de Reenvio<\/strong><\/a> \u2014 se a sua encomenda n\u00e3o chegar no prazo de 20 dias \u00fateis, reenviamo-la.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especifica\u00e7\u00e3o<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalhe<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Composi\u00e7\u00e3o<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Cagrilintida 5\u00a0mg + Semaglutida 5\u00a0mg por frasco (propor\u00e7\u00e3o de massa 1:1, coformulada)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pept\u00eddeo Total por Frasco<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">10\u00a0mg de massa total de pept\u00eddeo (5\u00a0mg + 5\u00a0mg)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00fameros CAS dos Componentes<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">1415456-99-3 (cagrilintida) \/ 910463-68-2 (semaglutida)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Perfil de Recetor<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Fam\u00edlia de recetores de amilina\/calcitonina (AMY1\/2\/3) <em>mais<\/em> Recetor GLP-1 \u2014 mecanicamente complementar, n\u00e3o sobreposto<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">P\u00f3 coformulado liofilizado (branco a branco acinzentado)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (cada componente verificado por HPLC, COA mediante pedido)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Meia-vida (por componente)<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Cagrilintida ~159 horas; Semaglutida ~165 horas \u2014 ambos suportando dosagem subcut\u00e2nea semanal<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Armazenamento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C (frigor\u00edfico) para stock de trabalho; \u221220 \u00b0C para armazenamento a longo prazo de frascos n\u00e3o abertos. Reconstitu\u00eddo: 2\u20138 \u00b0C, utilizar no prazo de ~30 dias. Proteger da luz. N\u00e3o congelar-descongelar a solu\u00e7\u00e3o reconstitu\u00edda.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidade<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u00c1gua bacteriost\u00e1tica (recomendada). Ambos os pept\u00eddeos reconstituem-se simultaneamente a partir do mesmo frasco.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>O que \u00e9 CagriSema?<\/h2>\n<p><strong>CagriSema<\/strong> \u00e9 o nome de desenvolvimento da Novo Nordisk para a combina\u00e7\u00e3o de propor\u00e7\u00e3o fixa de dois pept\u00eddeos de a\u00e7\u00e3o prolongada numa \u00fanica formula\u00e7\u00e3o subcut\u00e2nea: <a href=\"https:\/\/medsbase.com\/pt-pt\/cagrilintide\/\">cagrilintida<\/a> (o an\u00e1logo de amilina de a\u00e7\u00e3o prolongada, c\u00f3digo de desenvolvimento AM833) e <a href=\"https:\/\/medsbase.com\/pt-pt\/semaglutide\/\">semaglutide<\/a> (o agonista do recetor GLP-1 de a\u00e7\u00e3o prolongada comercializado como Ozempic e Wegovy como agente isolado). A combina\u00e7\u00e3o \u00e9 o principal programa de obesidade em Fase 3 no pipeline da Novo Nordisk e reportou os resultados do ensaio REDEFINE-1 em 2024\u20132025: aproximadamente 20\u201323% de redu\u00e7\u00e3o de peso corporal ao longo de 68 semanas na dose semanal de 2,4 mg + 2,4 mg \u2014 magnitudes de efeito que colocam o CagriSema na mesma gama que o agonista triplo de recetores <a href=\"https:\/\/medsbase.com\/pt-pt\/retatrutide\/\">retatrutide<\/a> while taking a completely different pharmacological route. The strategic rationale for CagriSema rests on the <strong>mecanismos complementares e n\u00e3o sobrepostos<\/strong> of its two component peptides. GLP-1 receptor agonists (semaglutide) act predominantly on hypothalamic arcuate-nucleus POMC neurons (central appetite regulation) and pancreatic beta-cells (glucose-dependent insulin secretion). Amylin\/calcitonin receptor agonists (cagrilintide) act predominantly on brainstem area-postrema neurons (per-meal satiety reinforcement) and pancreatic alpha-cells (glucagon suppression). The two mechanisms are mechanistically additive rather than redundant, which is why the combination produces body-weight effects substantially greater than either component alone \u2014 demonstrated in the Phase 2 head-to-head data where CagriSema outperformed both cagrilintide monotherapy and semaglutide monotherapy. This pharmaceutical-grade CagriSema co-formulation contains <strong>5 mg de cagrilintida + 5 mg de semaglutida por frasco<\/strong> numa propor\u00e7\u00e3o de massa 1:1 correspondente \u00e0 dose fixa utilizada no programa cl\u00ednico de Fase 3. Ambos os componentes est\u00e3o pr\u00e9-misturados no mesmo frasco liofilizado; a reconstitui\u00e7\u00e3o com \u00e1gua bacteriost\u00e1tica produz uma solu\u00e7\u00e3o de trabalho contendo ambos os p\u00e9ptidos simultaneamente. Esta abordagem elimina a necessidade de combinar frascos separados no laborat\u00f3rio. O CagriSema n\u00e3o est\u00e1 <strong>aprovado<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use as of current literature; regulatory submission and review are ongoing. For deeper detail on each component, see our individual <a href=\"https:\/\/medsbase.com\/pt-pt\/cagrilintide\/\">Cagrilintide<\/a> e <a href=\"https:\/\/medsbase.com\/pt-pt\/semaglutide\/\">Semaglutide<\/a> p\u00e1ginas de produtos. <\/p>\n<h2>Mecanismo de A\u00e7\u00e3o \u2014 Farmacologia Dual Complementar<\/h2>\n<p>What makes CagriSema mechanistically distinctive among current metabolic-compounds is that the two component peptides activate <strong>fam\u00edlias de recetores completamente diferentes com mecanismos centrais e perif\u00e9ricos n\u00e3o sobrepostos<\/strong> \u2014 alcan\u00e7ando uma farmacologia multi-eixo atrav\u00e9s da combina\u00e7\u00e3o, em vez de atrav\u00e9s da engenharia de uma \u00fanica mol\u00e9cula multi-agonista como o tirzepatide ou o retatrutide:<\/p>\n<ul>\n<li><strong>Bra\u00e7o do recetor GLP-1 (semaglutide) \u2014 regula\u00e7\u00e3o central do apetite e controlo glic\u00e9mico<\/strong> \u2014 Semaglutide activates the GLP-1 receptor on hypothalamic arcuate-nucleus POMC neurons (suppressing food intake via the central appetite system), pancreatic beta-cells (glucose-dependent insulin secretion), pancreatic alpha-cells (glucagon suppression), and gastric vagal afferents (delayed gastric emptying). This arm provides the canonical incretin pharmacology that semaglutide and other GLP-1 agonists are known for in published studies and approved clinical use.<\/li>\n<li><strong>Bra\u00e7o do recetor da amilina\/calcitonina (cagrilintide) \u2014 saciedade do tronco cerebral e feedback por refei\u00e7\u00e3o<\/strong> \u2014 O Cagrilintide ativa os heterod\u00edmeros do recetor da amilina (AMY1, AMY2, AMY3 \u2014 recetor da calcitonina + RAMP1\/2\/3) localizados densamente na \u00e1rea postrema do tronco cerebral, uma regi\u00e3o do SNC que n\u00e3o possui barreira hematoencef\u00e1lica. Isto produz um refor\u00e7o da saciedade por refei\u00e7\u00e3o num padr\u00e3o temporal diferente da supress\u00e3o central do apetite t\u00f3nica do GLP-1. O bra\u00e7o da amilina tamb\u00e9m retarda o esvaziamento g\u00e1strico atrav\u00e9s de uma via vagal parcialmente distinta e suprime o glucagon p\u00f3s-prandial nas c\u00e9lulas alfa pancre\u00e1ticas.<\/li>\n<li><strong>Efeito aditivo vs sin\u00e9rgico no fen\u00f3tipo do peso corporal<\/strong> \u2014 Os dados da Fase 2 head-to-head s\u00e3o a evid\u00eancia mais clara de farmacologia aditiva (e possivelmente sin\u00e9rgica): a monoterapia com cagrilintide a 2,4 mg semanais produziu uma redu\u00e7\u00e3o de ~10% no peso corporal; a monoterapia com semaglutide a 2,4 mg semanais produziu ~15%; a combina\u00e7\u00e3o CagriSema a 2,4 + 2,4 mg produziu ~20\u201323%. O efeito l\u00edquido aproxima-se ou excede a soma dos efeitos individuais, consistente com a previs\u00e3o mecanicista de que duas vias de saciedade n\u00e3o sobrepostas ativadas simultaneamente produzem um sinal anor\u00e9tico mais forte do que qualquer uma delas sozinha.<\/li>\n<\/ul>\n<p>Ambos os pept\u00eddeos s\u00e3o acilados com cadeias de \u00e1cido gordo que se ligam reversivelmente \u00e0 albumina s\u00e9rica circulante (o cagrilintide usa uma cadeia C20 via \u03b3-Glu-OEG-OEG; o semaglutide usa C18 via \u03b3-Glu-AEEA-AEEA). As meias-vidas est\u00e3o bem correspondidas em ~159 horas (cagrilintide) e ~165 horas (semaglutide) \u2014 ambas suportando a dose subcut\u00e2nea semanal sem farmacocin\u00e9tica divergente. Este alinhamento farmacocin\u00e9tico \u00e9 uma das caracter\u00edsticas de design que torna a coformula\u00e7\u00e3o num \u00fanico frasco pr\u00e1tica: os dois componentes podem ser reconstitu\u00eddos, armazenados e dosados em conjunto sem comprometer o perfil de exposi\u00e7\u00e3o de qualquer um. <\/p>\n<h2>Published Evidence<\/h2>\n<p>CagriSema co-formulation peptides are used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Farmacologia da obesidade em combina\u00e7\u00e3o<\/strong> \u2014 o programa principal: modelos pr\u00e9-cl\u00ednicos de roedores DIO, composi\u00e7\u00e3o corporal (DEXA\/RMN), ensaios de ingest\u00e3o alimentar, caracteriza\u00e7\u00e3o do gasto energ\u00e9tico; head-to-head contra bra\u00e7os de monoterapia (cagrilintide sozinho, semaglutide sozinho) para dissecar a quest\u00e3o aditiva vs sin\u00e9rgica (Enebo et al., Lancet 2021; resultados da Fase 3 REDEFINE-1 \/ REDEFINE-2)<\/li>\n<li><strong>Type 2 diabetes preclinical studies<\/strong> \u2014 controlo glic\u00e9mico, substitutos da HbA1c, din\u00e2mica da glucose p\u00f3s-prandial em modelos de roedores db\/db e com dieta rica em gorduras<\/li>\n<li><strong>Comparative multi-agonist studies<\/strong> \u2014 compara\u00e7\u00e3o direta com multi-agonistas de mol\u00e9cula \u00fanica, incluindo <a href=\"https:\/\/medsbase.com\/pt-pt\/tirzepatide\/\">Tirzepatide<\/a> (duplo GLP-1\/GIP), <a href=\"https:\/\/medsbase.com\/pt-pt\/retatrutide\/\">Retatrutide<\/a> (triplo GLP-1\/GIP\/glucagon), <a href=\"https:\/\/medsbase.com\/pt-pt\/mazdutide\/\">Mazdutide<\/a> (duplo GLP-1\/glucagon), e <a href=\"https:\/\/medsbase.com\/pt-pt\/survodutide\/\">Survodutide<\/a> (duplo GLP-1\/glucagon); a quest\u00e3o central \u00e9 se a farmacologia de combina\u00e7\u00e3o de duas mol\u00e9culas tem alguma vantagem sobre mol\u00e9culas multi-agonistas \u00fanicas<\/li>\n<li><strong>Amylin \/ GLP-1 axis interaction studies<\/strong> \u2014 caracteriza\u00e7\u00e3o de mecanismos n\u00e3o sobrepostos, disseca\u00e7\u00e3o de circuitos centrais de apetite no tronco cerebral versus hipot\u00e1lamo, ensaios de ocupa\u00e7\u00e3o simult\u00e2nea de recetores<\/li>\n<li><strong>Esvaziamento g\u00e1strico e fisiologia p\u00f3s-prandial<\/strong> \u2014 tempo de esvaziamento g\u00e1strico sob tratamento combinado versus individual, din\u00e2mica da glucose p\u00f3s-prandial, integra\u00e7\u00e3o do eixo hormonal intestinal<\/li>\n<li><strong>Energy expenditure studies<\/strong> \u2014 disp\u00eandio energ\u00e9tico em repouso, r\u00e1cio de troca respirat\u00f3ria; a combina\u00e7\u00e3o CagriSema produz um perfil distinto dos multi-agonistas que cont\u00eam recetor de glucagon (mazdutide, retatrutide) porque nenhum dos componentes ativa o recetor de glucagon<\/li>\n<li><strong>Combination-pharmacology design studies<\/strong> \u2014 CagriSema como estudo de caso em formula\u00e7\u00e3o multi-pept\u00eddica de propor\u00e7\u00e3o fixa, compara\u00e7\u00e3o da farmacocin\u00e9tica de coformula\u00e7\u00e3o versus frascos separados administrados sequencialmente ou em conjunto.<\/li>\n<\/ul>\n<p>Para um contexto mais amplo, consulte as nossas p\u00e1ginas <a href=\"https:\/\/medsbase.com\/pt-pt\/cagrilintide\/\">Cagrilintide<\/a> e <a href=\"https:\/\/medsbase.com\/pt-pt\/semaglutide\/\">Semaglutide<\/a> individuais de produtos para farmacologia ao n\u00edvel dos componentes, <a href=\"https:\/\/medsbase.com\/pt-pt\/retatrutide\/\">Retatrutide<\/a> como a principal alternativa de triplo agonista de mol\u00e9cula \u00fanica, e <a href=\"https:\/\/medsbase.com\/pt-pt\/tirzepatide\/\">Tirzepatide<\/a> como o comparador dual GLP-1\/GIP. Navegue pela lista completa de <a href=\"https:\/\/medsbase.com\/pt-pt\/peptides\/\">cat\u00e1logo de p\u00e9ptidos<\/a> para encontrar compostos relacionados. <\/p>\n<h2>Configura\u00e7\u00f5es Dispon\u00edveis<\/h2>\n<p>A MedsBase disponibiliza a mistura CagriSema numa \u00fanica coformula\u00e7\u00e3o: <strong>5 mg de cagrilintida + 5 mg de semaglutida por frasco<\/strong> at the clinical 1:1 mass ratio. The vial is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Composi\u00e7\u00e3o do Frasco<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de uso t\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tamanhos das embalagens<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5\u00a0mg + 5\u00a0mg<\/strong> (cagri + sema)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard CagriSema studies blend \u2014 combination obesity, T2DM, and additive-pharmacology studies at the clinical 1:1 mass ratio<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Both components are supplied at \u226599% HPLC purity (each verified individually) and pre-mixed in the same lyophilized vial. The 5\u00a0mg + 5\u00a0mg per vial composition supports approximately 2 weeks of clinical-equivalent dosing (2.4\u00a0mg + 2.4\u00a0mg weekly) per vial \u2014 a 10-vial pack covers approximately 20 weeks of studies at the Phase 3 maintenance dose. Compared with buying 10 vials of stand-alone Cagrilintide (5\u00a0mg) plus 10 vials of stand-alone Semaglutide (5\u00a0mg) separately, the co-formulated blend offers a modest cost saving and the practical convenience of single-vial reconstitution. <\/p>\n<h2>Como Compara \u2014 CagriSema vs Retatrutide<\/h2>\n<p>CagriSema e <a href=\"https:\/\/medsbase.com\/pt-pt\/retatrutide\/\">Retatrutide<\/a> are the two leading multi-mechanism approaches to maximum-magnitude body-weight effect in current metabolic-peptide studies. They take fundamentally different design approaches: CagriSema combines two single-receptor agonists in a fixed-dose blend, while retatrutide engineers triple-receptor pharmacology into a single molecule. The two reach comparable Phase 2\/3 body-weight effect sizes through these distinct routes \u2014 the comparison is one of the most-cited in current obesity-pharmacology studies. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e9rio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">CagriSema<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Retatrutide<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Abordagem de conce\u00e7\u00e3o<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Combina\u00e7\u00e3o de dois agonistas de recetor \u00fanico<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Mol\u00e9cula \u00fanica tripla-agonista<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Perfil de recetores<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + Amilina\/Calcitonina<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + GIP + Glucagon<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Componentes<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Cagrilintide + Semaglutide<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Mol\u00e9cula \u00fanica (LY3437943)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Desenvolvedor<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Novo Nordisk<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Eli Lilly<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Efeito no peso corporal<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~20\u201323% (REDEFINE-1, 68 semanas)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~24% (Fase 2, 48 semanas)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Alinhamento da meia-vida<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~159 \/ ~165 horas (bem correspondidas)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~6 dias (mol\u00e9cula \u00fanica, n\u00e3o necessita de correspond\u00eancia)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Amplitude do mecanismo<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Apetite central + saciedade do tronco cerebral + supress\u00e3o do glucagon<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Apetite central + lip\u00f3lise mediada por GIP + gasto energ\u00e9tico impulsionado pelo glucagon<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Gasto energ\u00e9tico<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Modesto (sem bra\u00e7o de glucagon)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Substancial (bra\u00e7o de glucagon)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The pharmacological choice between CagriSema and retatrutide depends on the studies question. For studies interested in maximum body-weight effect with the cleanest receptor-selectivity profile (no off-target GIP or glucagon signalling), CagriSema is the preferred reference. For studies interested in the additional mechanism breadth that glucagon-receptor activation provides (energy expenditure, hepatic lipid mobilisation), retatrutide is the canonical comparator. The combination-vs-single-molecule design question is itself an active area of pharmaceutical studies \u2014 both approaches have reached late-stage development, and Phase 3 head-to-head trials are likely to inform the long-term winner. <\/p>\n<h2>Armazenamento e Reconstitui\u00e7\u00e3o<\/h2>\n<p><strong>Antes da reconstitui\u00e7\u00e3o:<\/strong> armazenar frascos liofilizados refrigerados a 2\u20138 \u00b0C na embalagem original para estoque de trabalho a curto prazo. Para armazenamento a longo prazo n\u00e3o aberto, congelar a \u221220 \u00b0C. A coformula\u00e7\u00e3o liofilizada de CagriSema \u00e9 est\u00e1vel sob refrigera\u00e7\u00e3o por at\u00e9 24 meses e a \u221220 \u00b0C por at\u00e9 36 meses. Ambos os p\u00e9ptidos componentes t\u00eam perfis de estabilidade muito semelhantes, pelo que o armazenamento \u00e9 governado pelo p\u00e9ptido que degrada primeiro em determinadas condi\u00e7\u00f5es \u2014 na pr\u00e1tica, os dois componentes s\u00e3o notavelmente semelhantes. Evitar ciclos de congela\u00e7\u00e3o-descongela\u00e7\u00e3o no p\u00f3 liofilizado. <strong>Procedimento de reconstitui\u00e7\u00e3o:<\/strong> inject bacteriostatic water down the side wall of the vial (not directly onto the lyophilized cake). Because the vial contains 10\u00a0mg total peptide mass (5\u00a0mg cagri + 5\u00a0mg sema), a 2.0\u00a0mL reconstitution yields a 5\u00a0mg\/mL total-peptide working concentration \u2014 equivalent to 2.5\u00a0mg\/mL of each individual component. Approximately 0.96\u00a0mL delivers a 2.4\u00a0mg + 2.4\u00a0mg clinical-equivalent dose. Swirl gently \u2014 do <strong>n\u00e3o<\/strong> sacudir \u2014 e aguardar 5\u201310 minutos para dissolu\u00e7\u00e3o completa (ambos os p\u00e9ptidos s\u00e3o acilados e dissolvem-se mais lentamente do que p\u00e9ptidos menores n\u00e3o modificados). Uma solu\u00e7\u00e3o corretamente reconstitu\u00edda deve ser clara e incolor, sem part\u00edculas vis\u00edveis. <strong>Ap\u00f3s reconstitui\u00e7\u00e3o:<\/strong> armazenar refrigerado a 2\u20138 \u00b0C e utilizar dentro de 30 dias para estabilidade ideal de ambos os componentes. N\u00e3o congelar a solu\u00e7\u00e3o reconstitu\u00edda \u2014 os ciclos de congela\u00e7\u00e3o-descongela\u00e7\u00e3o degradam a integridade do p\u00e9ptido e podem afetar desproporcionalmente qualquer um dos componentes. Descartar qualquer frasco que apresente turva\u00e7\u00e3o, precipitado ou descolora\u00e7\u00e3o. <\/p>\n<h2 id=\"faqs\">Perguntas Frequentes<\/h2>\n<h3>What is CagriSema used for in studies?<\/h3>\n<p>CagriSema is used in studies investigating the additive pharmacology of GLP-1 and amylin receptor activation, combination obesity pharmacology, type 2 diabetes preclinical models, comparative head-to-head studies against single-molecule multi-agonists (tirzepatide, retatrutide, mazdutide, survodutide), and combination-pharmacology design questions. It is the lead Phase 3 combination-pharmacology compound in current metabolic-peptide studies from Novo Nordisk. The pharmaceutical-grade CagriSema sold here is <strong>n\u00e3o<\/strong> FDA-approved and is supplied strictly for clinical studies use only. <\/p>\n<h3>O que cont\u00e9m um frasco de CagriSema?<\/h3>\n<p>Cada frasco cont\u00e9m <strong>5 mg de cagrilintida e 5 mg de semaglutida<\/strong>, coformulados e liofilizados juntos como um \u00fanico p\u00f3. A propor\u00e7\u00e3o de massa 1:1 corresponde \u00e0 dose fixa utilizada no programa cl\u00ednico de Fase 3 do CagriSema (2,4 mg + 2,4 mg semanalmente). Ambos os pept\u00eddeos reconstituem-se simultaneamente quando se adiciona \u00e1gua bacteriost\u00e1tica. <\/p>\n<h3>Em que \u00e9 que o CagriSema difere da Cagrilintida isolada ou da Semaglutida isolada?<\/h3>\n<p>O CagriSema combina ambos os pept\u00eddeos num \u00fanico frasco. <a href=\"https:\/\/medsbase.com\/pt-pt\/cagrilintide\/\">A Cagrilintida isolada<\/a> activates only the amylin\/calcitonin receptor family and produces approximately 10% body-weight reduction in Phase 2 monotherapy studies. <a href=\"https:\/\/medsbase.com\/pt-pt\/semaglutide\/\">Semaglutide isolado<\/a> ativa apenas o recetor GLP-1 e produz uma redu\u00e7\u00e3o de peso corporal de aproximadamente 15% na monoterapia de Fase 3 (ensaios STEP). A combina\u00e7\u00e3o CagriSema produz aproximadamente 20\u201323% \u2014 mais do que qualquer um dos componentes isoladamente, porque os dois mecanismos n\u00e3o se sobrep\u00f5em (recetores diferentes, locais diferentes no SNC, efeitos perif\u00e9ricos complementares). <\/p>\n<h3>Como \u00e9 que o CagriSema difere do Retatrutide?<\/h3>\n<p>Ambos s\u00e3o abordagens l\u00edderes de m\u00faltiplos mecanismos para o efeito no peso corporal, mas seguem rotas de conce\u00e7\u00e3o fundamentalmente diferentes. O CagriSema combina dois agonistas de recetor \u00fanico separados (cagrilintide + semaglutide) num \u00fanico frasco \u2014 farmacologia de combina\u00e7\u00e3o. <a href=\"https:\/\/medsbase.com\/pt-pt\/retatrutide\/\">Retatrutide<\/a> engineers triple-receptor pharmacology (GLP-1 + GIP + glucagon) into a single molecule. Both reach approximately 20\u201324% body-weight effect at maintenance dose in Phase 2\/3 studies, but through different receptor sets \u2014 CagriSema uses GLP-1 + amylin, retatrutide uses GLP-1 + GIP + glucagon. <\/p>\n<h3>Porqu\u00ea combinar os dois p\u00e9ptidos num \u00fanico frasco?<\/h3>\n<p>Co-formulation has three practical advantages: (1) the half-lives of cagrilintide (~159 h) and semaglutide (~165 h) are well-matched, so a single weekly injection delivers both peptides on the same pharmacokinetic schedule; (2) reconstitution is simpler \u2014 one vial, one diluent volume, one withdrawal; (3) fixed-dose-ratio is straightforward because the dose ratio is set at manufacture and cannot drift between separate vial draws. The principal trade-off is that the dose ratio is fixed at 1:1 mass \u2014 for studies requiring different ratios, separate vials of <a href=\"https:\/\/medsbase.com\/pt-pt\/cagrilintide\/\">cagrilintida<\/a> e <a href=\"https:\/\/medsbase.com\/pt-pt\/semaglutide\/\">semaglutide<\/a> podem ser prefer\u00edveis. <\/p>\n<h3>What is the typical CagriSema dose?<\/h3>\n<p>Published Phase 3 clinical studies uses 2.4\u00a0mg cagrilintide + 2.4\u00a0mg semaglutide weekly as the maintenance dose, with a multi-month titration schedule starting at 0.25\u00a0mg + 0.25\u00a0mg. A vial reconstituted with 2.0\u00a0mL bacteriostatic water yields 2.5\u00a0mg\/mL of each component (5\u00a0mg\/mL total peptide mass) \u2014 approximately 0.96\u00a0mL equals a clinical-equivalent 2.4\u00a0mg + 2.4\u00a0mg dose. <\/p>\n<h3>O CagriSema est\u00e1 aprovado pela FDA?<\/h3>\n<p>No. CagriSema is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. The REDEFINE-1 (obesity) and REDEFINE-2 (T2DM) Phase 3 trials reported positive results in 2024\u20132025, but regulatory submission and review are ongoing. <\/p>\n<h3>Como deve ser armazenado o CagriSema?<\/h3>\n<p>Frasco liofilizado: refrigerado a 2\u20138 \u00b0C para stock de trabalho a curto prazo, ou \u221220 \u00b0C para armazenamento a longo prazo de frascos n\u00e3o abertos. Solu\u00e7\u00e3o reconstitu\u00edda: refrigerada a 2\u20138 \u00b0C, utilizar no prazo de 30 dias. N\u00e3o congelar a solu\u00e7\u00e3o reconstitu\u00edda \u2014 os ciclos de congela\u00e7\u00e3o-descongela\u00e7\u00e3o degradam a integridade do p\u00e9ptido e podem afetar desproporcionalmente qualquer um dos componentes. Proteger sempre da luz direta. <\/p>\n<h3>Como reconstituir o CagriSema?<\/h3>\n<p>Siga o procedimento de reconstitui\u00e7\u00e3o acima. Adicione \u00e1gua bacteriost\u00e1tica pela parede lateral do frasco (n\u00e3o diretamente sobre o p\u00f3 liofilizado), agite suavemente e aguarde 5\u201310 minutos para dissolu\u00e7\u00e3o completa (ambos os pept\u00eddeos s\u00e3o acilados e dissolvem-se mais lentamente do que pept\u00eddeos menores n\u00e3o modificados). N\u00e3o <strong>n\u00e3o<\/strong> agite o frasco. Ambos os pept\u00eddeos reconstituem-se simultaneamente a partir do mesmo frasco. Uma solu\u00e7\u00e3o corretamente reconstitu\u00edda \u00e9 clara e incolor, sem part\u00edculas vis\u00edveis. Para um frasco + 2,0 mL de diluente, a concentra\u00e7\u00e3o de trabalho \u00e9 de 2,5 mg\/mL de cada pept\u00eddeo. <\/p>\n<h3>Que configura\u00e7\u00f5es tem a MedsBase em stock?<\/h3>\n<p>MedsBase carries the CagriSema co-formulation in a single composition: 5\u00a0mg cagrilintide + 5\u00a0mg semaglutide per vial (1:1 mass ratio, lyophilized). The vial is available in 10-vial, 20-vial, or 30-vial pack sizes. Each component is verified individually at \u226599% HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>Posso comprar os componentes do CagriSema separadamente?<\/h3>\n<p>Sim \u2014 a MedsBase disponibiliza ambos os pept\u00eddeos como produtos individuais: <a href=\"https:\/\/medsbase.com\/pt-pt\/cagrilintide\/\">Cagrilintide<\/a> em frascos de 5 mg e 10 mg, e <a href=\"https:\/\/medsbase.com\/pt-pt\/semaglutide\/\">Semaglutide<\/a> in 2\u201350\u00a0mg vials. Separate vials are useful if protocols require dose ratios other than the clinical 1:1 mass ratio, or if users want to dose cagrilintide and semaglutide independently. The co-formulated blend offers a small bundle saving and the convenience of single-vial reconstitution for protocols at the 1:1 clinical ratio. <\/p>\n<h3>Does CagriSema cause side reported effects?<\/h3>\n<p>The side-effect profile of CagriSema in Phase 3 is dominated by gastrointestinal findings shared with both component peptides: nausea, transient appetite suppression, and delayed gastric emptying are dose-dependent and tend to attenuate over 4\u20138 weeks of continuous dosing. The combined regimen does not produce qualitatively different side effects from either component alone \u2014 the GI-axis tolerability is roughly comparable to semaglutide monotherapy at equivalent doses. <\/p>\n<h3>Qual \u00e9 a meia-vida do CagriSema?<\/h3>\n<p>Ambos os pept\u00eddeos componentes t\u00eam meias-vidas plasm\u00e1ticas muito pr\u00f3ximas: cagrilintida ~159 horas (~6,5 dias) e semaglutida ~165 horas (~7 dias). Esta correspond\u00eancia \u00e9 uma das caracter\u00edsticas de design que torna pr\u00e1tica a coformula\u00e7\u00e3o num \u00fanico frasco \u2014 ambos os pept\u00eddeos s\u00e3o eliminados da circula\u00e7\u00e3o no mesmo hor\u00e1rio, permitindo uma dosagem semanal sem farmacocin\u00e9tica divergente. O mecanismo de liga\u00e7\u00e3o \u00e0 albumina (acila\u00e7\u00e3o com \u00e1cido gordo C20 \/ C18) \u00e9 a base para a meia-vida prolongada em ambos os pept\u00eddeos. <\/p>\n<h3>How long does CagriSema take to show effects in preclinical studies?<\/h3>\n<p>Os efeitos farmacodin\u00e2micos agudos sobre o esvaziamento g\u00e1strico, a saciedade por refei\u00e7\u00e3o e a toler\u00e2ncia \u00e0 glucose s\u00e3o detet\u00e1veis poucas horas ap\u00f3s a primeira dose. Os efeitos sobre o peso corporal em modelos de roedores DIO tornam-se tipicamente estatisticamente significativos ap\u00f3s 1\u20132 semanas de dosagem semanal e continuam a acumular-se ao longo de 16\u201324 semanas. O efeito m\u00e1ximo sobre a composi\u00e7\u00e3o corporal desenvolve-se ao longo de 48\u201368 semanas, correspondendo \u00e0 trajet\u00f3ria da Fase 3 do REDEFINE-1. <\/p>\n<h3>Posso encomendar CagriSema para envio internacional?<\/h3>\n<p>Sim. A MedsBase envia CagriSema para todo o mundo atrav\u00e9s da nossa rede dedicada de envio de p\u00e9ptidos. As encomendas exclusivas de p\u00e9ptidos qualificam-se para o nosso servi\u00e7o de envio de p\u00e9ptidos independente. Todas as encomendas s\u00e3o enviadas em embalagens com controlo de temperatura, com rastreio completo e cobertas pela nossa <a href=\"https:\/\/medsbase.com\/pt-pt\/medsbase-re-shipment-assurance-policy\/\">Pol\u00edtica de Garantia de Reenvio<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Metabolic, Body-Composition, and Multi-Mechanism Studies<\/h2>\n<ul>\n<li><a href=\"\/pt-pt\/cagrilintide\/\"><strong>Cagrilintide<\/strong><\/a> \u2014 An\u00e1logo de amilina de a\u00e7\u00e3o prolongada \u2014 o componente de amilina do CagriSema, frascos independentes<\/li>\n<li><a href=\"\/pt-pt\/semaglutide\/\"><strong>Semaglutide<\/strong><\/a> \u2014 Agonista de GLP-1 de a\u00e7\u00e3o prolongada \u2014 o componente de GLP-1 do CagriSema, frascos independentes<\/li>\n<li><a href=\"\/pt-pt\/retatrutide\/\"><strong>Retatrutide<\/strong><\/a> \u2014 Agonista triplo de GLP-1\/GIP\/glucagon \u2014 alternativa de mol\u00e9cula \u00fanica multi-agonista<\/li>\n<li><a href=\"\/pt-pt\/tirzepatide\/\"><strong>Tirzepatide<\/strong><\/a> \u2014 Agonista duplo de GLP-1\/GIP \u2014 abordagem alternativa de m\u00faltiplos mecanismos<\/li>\n<li><a href=\"\/pt-pt\/mazdutide\/\"><strong>Mazdutide<\/strong><\/a> \u2014 Co-agonista duplo de GLP-1\/glucagon \u2014 alternativa derivada da oxintomodulina<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Leitura Adicional<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Explore o panorama metab\u00f3lico da farmacologia combinada<\/strong><\/p>\n<p style=\"margin: 0;\">Explore a gama completa <a href=\"https:\/\/medsbase.com\/pt-pt\/peptides\/\"><strong>cat\u00e1logo de p\u00e9ptidos<\/strong><\/a>, com compostos relacionados de combina\u00e7\u00e3o e m\u00faltiplos mecanismos, incluindo <a href=\"https:\/\/medsbase.com\/pt-pt\/cagrilintide\/\">Cagrilintide<\/a> (amilina independente), <a href=\"https:\/\/medsbase.com\/pt-pt\/semaglutide\/\">Semaglutide<\/a> (GLP-1 isolado), <a href=\"https:\/\/medsbase.com\/pt-pt\/retatrutide\/\">Retatrutide<\/a> (triplo agonista de mol\u00e9cula \u00fanica), e <a href=\"https:\/\/medsbase.com\/pt-pt\/mazdutide\/\">Mazdutide<\/a> (GLP-1\/glucag\u00e3o dual). Guia comparativo: <a href=\"https:\/\/medsbase.com\/pt-pt\/retatrutide-vs-tirzepatide\/\">Retatrutida vs Tirzepatida<\/a>.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Combina\u00e7\u00e3o coformulada de cagrilintida + semaglutida (1:1)<br \/>\n\u2705 Ambos os pept\u00eddeos num \u00fanico frasco (5 mg + 5 mg)<br \/>\n\u2705 Combina\u00e7\u00e3o l\u00edder da Novo Nordisk para obesidade na Fase 3<br \/>\n\u2705 Efeito de ~20\u201323% no peso corporal (REDEFINE-1)<br \/>\n\u2705 Mecanismos complementares de amilina + GLP-1<\/p>\n<p><strong>CagriSema<\/strong> \u00e9 uma mistura coformulada de pept\u00eddeos.<\/p>","protected":false},"featured_media":70943,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6284,6287,5441,3846],"class_list":["post-70765","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-cagrilintide","product_tag-cagrisema","product_tag-peptide","product_tag-semaglutide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product\/70765","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/comments?post=70765"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/media\/70943"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/media?parent=70765"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_brand?post=70765"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_cat?post=70765"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_tag?post=70765"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}